Clinical Trial

Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is a an open-label, multinational, multicenter, single-arm Phase Ⅰb/Ⅱ Study to Evaluate Efficacy and Safety of Oral HH2853 in Patients with Relapsed/Refractory Peripheral T-cell Lymphoma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-27; most recent amendment 2026-01-28.
Trial Details
NCT Number NCT06909877
Lead Sponsor Haihe Biopharma Co., Ltd.
Conditions Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
Enrollment 100 participants
Start Date 2022-07-27
Primary Completion 2025-10-31 (estimated)
Study Completion 2027-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-30